| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-063 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于部分董事、高级管理人员减持股份计划的 提示性公告 持有仙乐健康科技股份有限公司（以下简称"公司"或"仙乐健康"）股份 9,925,961 股（约占公司总股本 3.24%）的公司董事杨睿女士计划在本公告披露 之日起十五个交易日后的三个月内以大宗交易或集中竞价方式减持公司股份不 超过 2,481,491 股（约占公司总股本 0.81%）。若计划实施期间有送股、资本公 积金转增股本等股份变动事项，减持股份数量将相应进行调整。 公司于近日收到公司董事、副总经理姚壮民先生和公司董事杨睿女士各自出 具的《关于减持股份计划的告知函》。现将相关情况公告如下： 1 一、股东基本情况 减持股东的基本情况如下： 公司董事、副总经理姚壮民先生保证向本公司提供的信息真实、准确、完 整，没有虚假记载、误导性陈述或重大遗漏。 公司董事杨睿女士保证向本公司提供的信息真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 本公 ...

| 证券代码：300791 | 证券简称：仙乐健康 | 公告编码：2025-062 | | --- | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | | 仙乐健康科技股份有限公司 关于调整仙乐转债转股价格的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 重要提示： 债券代码：123113 债券简称：仙乐转债 调整前转股价格：人民币 31.82 元/股 调整后转股价格：人民币 31.88 元/股 转股价格调整起始日期：2025 年 7 月 4 日 一、转股价格调整依据 根据仙乐健康科技股份有限公司（以下简称"公司"）《创业板向不特定对 象发行可转换公司债券募集说明书》（以下简称"《募集说明书》"）发行条款 及中国证监会关于可转换公司债券发行的有关规定，仙乐转债发行之后，若公司 发生增发新股情况，则转股价格相应调整。具体的转股价格调整公式如下： 增发新股或配股：P1=（P0+A×k）/（1+k）； 其中：P0 为调整前转股价，k 为增发新股或配股率，A 为增发新股价或配股 价，P1 为调整后转股价。 1 2022 年 5 月 ...

关于 2023 年限制性股票激励计划部分已授予但尚未解 除限售的限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、仙乐健康科技股份有限公司（以下简称"仙乐健康"、"公司"或"本 公司"）本次回购注销的限制性股票数量为 751,712 股，占本次回购注销前总股 本 308,070,672 股的 0.24%。本次回购注销涉及 78 名激励对象。 2、截至本公告披露日，公司已在中国证券登记结算有限责任公司深圳分公 司办理完成上述限制性股票的回购注销手续。 3、本次回购注销完成后，公司总股本由 308,070,672 股减少为 307,318,960 股。 | 证券代码：300791 | 证券简称：仙乐健康 公告编码：2025-061 | | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | 仙乐健康科技股份有限公司 公司于 2025 年 4 月 16 日召开第四届董事会第八次会议和第四届监事会第 六次会议，于 2025 年 5 月 8 日召开 2024 年年度股东大会，分别审议通过了《关 于回 ...

| 证券代码：300791 | 证券简称：仙乐健康 公告编码：2025-060 | | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | 关于 2025 年第二季度取得 发明专利证书和保健食品注册证书、备案凭证的公告 仙乐健康科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 仙乐健康科技股份有限公司（以下简称"公司"或"仙乐健康"）及公司子 公司在 2025 年第二季度取得 4 项发明专利证书（其中 3 项中国发明专利，1 项 为美国发明专利）、2 项保健食品注册证书和 9 项保健食品备案凭证。具体情况 如下： 一、专利及专利使用权 截至 2025 年 6 月 30 日，公司及子公司拥有 159 项专利，其中 94 项是发明 专利。2025 年 4 月 1 日至 2025 年 6 月 30 日，公司及子公司新增 4 项发明专 利，新增发明专利如下： | 序号 | 专利名称 | 专利号 | 类别 | 取得 | 取得时间 | 专利权人 | 有效期限 至 | | --- | --- | --- | --- | --- | ...

| 证券代码：300791 | 证券简称：仙乐健康 公告编码：2025-059 | | --- | --- | | 债券代码：123113 | 债券简称：仙乐转债 | 仙乐健康科技股份有限公司 关于 2025 年第二季度可转债转股情况的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、"仙乐转债"（债券代码：123113）转股期为 2021 年 10 月 25 日至 2027 年 4 月 18 日；最新有效的转股价格为 31.82 元/股。 2、2025 年第二季度，共有 0 张"仙乐转债"完成转股（票面金额共计 0 元人民币），合计转成 0 股"仙乐健康"股票（股票代码：300791）。 3、截至 2025 年第二季度末，公司剩余可转债为 10,248,194 张，剩余可转 债票面总金额为 1,024,819,400 元人民币。 根据《深圳证券交易所创业板股票上市规则》等相关规定和《仙乐健康科 技股份有限公司向不特定对象发行可转换公司债券募集说明书》（以下简称"募 集说明书"）的相关规定，本次发行的可转换公司债券转股期自可转换公司债券 发 ...

Core Insights - The demand for grape seed health products is increasing due to rising living standards and health awareness among consumers [1][16] - The market size of grape seed health products in China is projected to grow from 5 billion yuan in 2019 to 9 billion yuan by 2024, with a compound annual growth rate of 12% [1][16] - Technological advancements in extraction efficiency and purity are supporting the growth of the grape seed health product market [1][16] Industry Overview - Grape seed health products are derived from grape seeds and contain beneficial components such as vitamins, minerals, amino acids, and antioxidants, offering various health benefits [3][10] - The industry can be categorized by product form (tablets, capsules, liquid), efficacy (antioxidant, anti-aging), and usage scenarios (daily health, beauty, sports nutrition) [5][10] Market Dynamics - The grape seed health product market is experiencing rapid expansion due to the growth of e-commerce and diversified marketing channels [1][16] - The increase in grape production in China, from 13.16 million tons in 2015 to 16.17 million tons in 2023, is expected to provide ample raw materials for grape seed health products [12][14] Regulatory Environment - Recent policies in China aim to promote the integration of the food industry with health and wellness sectors, enhancing the market for functional foods and health products [6][9] Competitive Landscape - Major players in the grape seed health product market include well-known domestic brands such as汤臣倍健 (Tongrentang), 康恩贝 (Kang En Bei), and 九芝堂 (Jiu Zhi Tang), as well as international brands like Nature's Way and NOW Foods [18][19] - Companies are enhancing their competitiveness through improved production technologies and brand marketing strategies [18][19] Consumer Trends - There is a notable increase in consumer demand for high-quality grape seed health products, particularly among women and young adults aged 18 to 35, who represent 83.7% of the health supplement market [24][25] - Consumers are increasingly focused on product quality, efficacy, and safety, necessitating continuous improvement in product formulations [24][25] Future Outlook - The industry is expected to benefit from technological advancements that enhance product absorption and bioavailability [25][26] - The trend of online and offline integration in sales channels is becoming crucial for market growth, providing consumers with a more convenient shopping experience [26][27] - International expansion is a growing trend, with Chinese companies leveraging their resources and technology to compete in global markets [27]

Core Viewpoint - The credit rating report for Xianle Health Technology Co., Ltd. indicates a stable credit rating of AA- with a focus on the company's strong production capabilities and market position in the nutritional health food sector [3][6][11]. Company Overview - Xianle Health specializes in B-end business as a significant contract manufacturer of nutritional health foods, with a diverse product line including soft capsules, gummies, beverages, tablets, powders, and hard capsules [3][17]. - The company has established seven production bases and five R&D centers across China, Europe, and the United States, enhancing its manufacturing and research capabilities [5][17]. Financial Performance - In 2024, the company achieved total revenue of 42.11 billion yuan, representing a year-on-year growth of 17.56%, with a gross profit margin of 31.46% [5][22]. - Key financial metrics include total assets of 56.14 billion yuan and total liabilities of 16.19 billion yuan as of 2024 [3][22]. Market Position and Growth - The global nutritional health food market is projected to grow, with the Chinese market expected to reach 260.2 billion yuan in 2024, reflecting a compound annual growth rate of 6.3% from 2019 to 2024 [11][12]. - The company has seen a significant increase in overseas revenue, which accounted for 60.56% of total revenue by the end of 2024, driven by sales growth in the Americas [22]. Product and R&D Capabilities - The company has over 6,000 mature nutritional health food formulations and has received multiple health food registration certificates, indicating strong product development capabilities [17][16]. - R&D expenses increased by 13.98% in 2024, showcasing the company's commitment to innovation and product development [16]. Debt and Financial Stability - The company's debt structure is considered reasonable, with a strong ability to generate cash flow from operations, and a good EBITDA interest coverage ratio [6][22]. - The company issued 10.25 billion yuan in convertible bonds to fund expansion projects, with a portion of the funds redirected to supplement working capital [8][9]. Industry Environment - The nutritional health food industry is supported by government policies promoting health management and the "Healthy China" initiative, which is expected to drive market growth [12][11]. - New consumption trends, including online and cross-border sales channels, are emerging, with a notable increase in the online penetration rate of nutritional health products [13][14].

信用评级报告声明 除因本次评级事项本评级机构与评级对象构成委托关系外，本评级机构及评级从业人员与评级对象不存 在任何足以影响评级行为独立、客观、公正的关联关系。 本评级机构与评级从业人员已履行尽职调查义务，有充分理由保证所出具的评级报告遵循了真实、客观、 公正原则，但不对评级对象及其相关方提供或已正式对外公布信息的合法性、真实性、准确性和完整性 作任何保证。 本评级机构依据内部信用评级标准和工作程序对评级结果作出独立判断，不受任何组织或个人的影响。 仙乐健康科技股份有限公司相关 债券 2025 年跟踪评级报告 中鹏信评【2025】跟踪第【157】号 01 本评级报告观点仅为本评级机构对评级对象信用状况的个体意见，不作为购买、出售、持有任何证券的 建议。本评级机构不对任何机构或个人因使用本评级报告及评级结果而导致的任何损失负责。 本次评级结果自本评级报告所注明日期起生效，有效期为被评证券的存续期。同时，本评级机构已对受 评对象的跟踪评级事项做出了明确安排，并有权在被评证券存续期间变更信用评级。本评级机构提醒报 告使用者应及时登陆本公司网站关注被评证券信用评级的变化情况。 本评级报告版权归本评级机构所有，未经授权 ...

Investment Rating - The investment rating for the industry is "Increase" for key stocks such as Xianle Health and Tongrentang [6]. Core Insights - The health consumption trend is rising, with the nutrition and health product category maintaining rapid growth. The total sales for nutrition and health products during the 618 shopping festival in 2025 are projected to reach 14.3 billion yuan, a 55% increase from 9.2 billion yuan in 2024 [1]. - Emerging channels like instant retail are performing well, with Meituan reporting over a 200% year-on-year increase in orders for health supplements [1]. - Traditional categories are expanding steadily, with high-growth segments like anti-aging and liver protection showing significant sales growth [2]. - Leading brands such as Swisse and Tongrentang maintain their positions, while new brands are emerging with competitive pricing and niche market strategies [3]. Summary by Sections Industry Overview - The nutrition and health product sector is experiencing robust growth, driven by health-conscious consumer behavior and the rise of e-commerce and new retail channels [1]. Product Categories - Key categories with strong sales during the 618 festival include infant nutrition products, special medical foods, and fish oil. Anti-aging products are among the fastest-growing segments [2]. Brand Analysis - The top brands on platforms like Tmall and JD remain consistent, with Swisse and Tongrentang leading. New entrants are gaining traction by focusing on quality and cost-effectiveness [3]. Investment Recommendations - The report suggests focusing on companies with clear competitive advantages in the contract manufacturing segment, such as Xianle Health and Baihe Shares, and high-quality brand operators like H&H International Holdings and Tongrentang [4].

证券代码：300791 证券简称：仙乐健康 公告编码：2025-058 债券代码：123113 债券简称：仙乐转债 仙乐健康科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现增加、否决或变更议案的情形； 2、本次股东大会不涉及变更以往股东大会已通过的决议。 一、 会议召开情况 1、现场会议召开时间：2025 年 6 月 12 日（星期四）14:30 2、现场会议召开地点：汕头市龙湖区泰山路 83 号公司行政楼会议室 3、网络投票时间：2025 年 6 月 12 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 6 月 12 日 9:15-9:25，9:30-11:30 和 13:00-15:00； 通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 6 月 12 日 9:15-15:00 期间的任意时间。 6、会议的召集、召开与表决程序符合《中华人民共和国公司法》、《深 圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律监 ...